无症状颈动脉狭窄:单纯最佳药物治疗是否充分的误区
该综述回顾了无症状颈动脉狭窄(ACS)患者单纯药物治疗与附加颈动脉内膜剥脱术(CEA)或支架置入术(CAS)的证据,指出目前仅有限人群(特定男性、60%以上狭窄)从CEA获益,而常用高卒中风险标志物缺乏特异性且未在随机试验中验证其筛选获益者的价值,强调需基于当前最佳药物治疗重新分层研究。
要点
- 仅特定平均手术风险、<75-80岁、60%以上狭窄男性可能从CEA获益。
- 常用高卒中风险标志物缺乏特异性,未在随机试验中验证筛选价值。
- 需基于当前最佳药物治疗开展卒中风险分层研究以识别获益人群。
核心结论
- 药物治疗在ACS常规管理中已确立作用,但需重新评估附加颈动脉手术的获益人群。
研究设计与样本
- 综述,回顾ACS患者单纯药物治疗与附加CEA或CAS的随机试验及观察性证据。
主要发现
- 随机试验显示CEA对ACS的卒中预防获益仅见于特定平均手术风险、<75-80岁、60%以上狭窄男性(NASCET标准)。
- 近期ACS单纯药物治疗的卒中率总体低于随机试验中CEA或CAS组的卒中率。
- CEA与CAS的随机试验把握度不足,但CAS有卒中和死亡 rates 更高的趋势。
- 常用高卒中风险标志物缺乏特异性,未与当前最佳药物治疗联合评估,且未在随机试验中验证。
临床怎么用
- 对ACS患者应优先优化药物治疗,谨慎选择附加颈动脉手术,尤其非特定获益人群。
- 不应仅凭常用高卒中风险标志物决定是否行CEA或CAS。
局限性
- 缺乏当前最佳药物治疗与CEA或CAS直接比较的随机试验结果。
- CEA与CAS的随机试验把握度不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Medical intervention (risk factor identification, lifestyle coaching, and medication) for stroke prevention has improved significantly. It is likely that no more than 5.5% of persons with advanced asymptomatic carotid stenosis (ACS) will now benefit from a carotid procedure during their lifetime. However, some question the adequacy of medical intervention alone for such persons and propose using markers of high stroke risk to intervene with carotid endarterectomy (CEA) and/or carotid angioplasty/stenting (CAS). Our aim was to examine the scientific validity and implications of this proposal. METHODS: We reviewed the evidence for using medical intervention alone or with additional CEA or CAS in persons with ACS. We also reviewed the evidence regarding the validity of using commonly cited makers of high stroke risk to select such persons for CEA or CAS, including markers proposed by the European Society for Vascular Surgery in 2017. RESULTS: Randomized trials of medical intervention alone versus additional CEA showed a definite statistically significant CEA stroke prevention benefit for ACS only for selected average surgical risk men aged less than 75 to 80 years with 60% or greater stenosis using the North American Symptomatic Carotid Endarterectomy Trial criteria. However, the most recent measurements of stroke rate with ACS using medical intervention alone are overall lower than for those who had CEA or CAS in randomized trials. Randomized trials of CEA versus CAS in persons with ACS were underpowered. However, the trend was for higher stroke and death rates with CAS. There are no randomized trial results related to comparing current optimal medical intervention with CEA or CAS. Commonly cited markers of high stroke risk in relation to ACS lack specificity, have not been assessed in conjunction with current optimal medical intervention, and have not been shown in randomized trials to identify those who benefit from a carotid procedure in addition to current optimal medical intervention. CONCLUSIONS: Medical intervention has an established role in the current routine management of persons with ACS. Stroke risk stratification studies using current optimal medical intervention alone are the highest research priority for identifying persons likely to benefit from adding a carotid procedure.
引用
- Abbott AL, Brunser AM, Giannoukas A, et al. Misconceptions regarding the adequacy of best medical intervention alone for asymptomatic carotid stenosis. J Vasc Surg. 2019. PMID: 31564585. doi:10.1016/j.jvs.2019.04.490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。